HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study
MWN-AI** Summary
HeartBeam, Inc. (NASDAQ: BEAT) has announced the successful enrollment of the first patients in its ALIGN-ACS pilot study, which focuses on the innovative HeartBeam System designed for non-traditional heart attack detection. Conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia, the pilot study aims to evaluate the HeartBeam System’s ability to detect heart attacks alongside a standard 12-lead ECG.
Heart attacks are a leading cause of death in the U.S., with over 20 million patients at risk. Patients often delay seeking care due to vague symptoms, which can exacerbate outcomes. Traditional methods of heart attack diagnosis, such as the 12-lead ECG, are limited to clinical settings, creating a gap that HeartBeam aims to bridge. The HeartBeam System can record clinical-grade ECG data at the onset of symptoms, potentially reducing the time it takes for patients to receive care.
The pilot study plans to enroll 100 patients presenting with chest pain in emergency rooms, comparing results from both the HeartBeam device and standard ECGs to determine accuracy against final diagnoses. Early insights from this study could shape a larger pivotal study critical for future FDA submissions.
Robert Eno, the CEO of HeartBeam, emphasizes the importance of their technology in transforming cardiac care and facilitating timely interventions. With FDA clearance for arrhythmia assessment and ongoing developments in their technology, HeartBeam is positioned strategically within a substantial market opportunity.
The ALIGN-ACS pilot study signifies a major advancement in HeartBeam's efforts to enhance accessibility and intelligence in cardiac health management, ultimately aiming to empower both patients and physicians in emergency scenarios.
MWN-AI** Analysis
HeartBeam, Inc. (NASDAQ: BEAT) has recently announced a significant advancement with the enrollment of its first patients in the ALIGN-ACS pilot study, aimed at evaluating its innovative technology for heart attack detection. This development is pivotal as it underscores HeartBeam's potential to revolutionize cardiac care by enabling heart attack assessments outside of conventional clinical settings.
As heart attacks remain the leading cause of death, with over 20 million patients at risk in the U.S. alone, HeartBeam's ability to provide clinical-grade ECG insights through its unique 3D ECG technology represents a transformative approach to patient care. The capability to perform diagnostics in real-time and outside of hospital environments could drastically reduce the critical "symptom-to-door" time, potentially saving lives and lowering healthcare costs associated with delayed treatments.
From a market perspective, the initiation of the ALIGN-ACS study could serve as a catalyst for HeartBeam’s growth trajectory. If the pilot demonstrates reliable results, it paves the way for a multicenter pivotal study, leading to potential FDA submissions for expanded indications. Should this occur, HeartBeam stands to unlock access to a vast market composed of millions of patients, enhancing its competitive position in an industry that’s increasingly prioritizing innovative, easily accessible healthcare solutions.
Investors may wish to observe HeartBeam's upcoming milestones closely, particularly regarding study results and regulatory advancements. Given the promising nature of their technology and the sheer size of the addressable market, HeartBeam offers an intriguing proposition for those looking to invest in the future of cardiac healthcare. As with any emerging technology, potential investors should be cognizant of associated risks and allow for a diversified approach in their portfolios.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings
- ALIGN-ACS study expected to complete patient enrollment quickly
- Milestone signifies key step toward future FDA indication expansion for heart attack assessment
- Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia. The initiation of the ALIGN-ACS pilot study represents a significant step toward collecting the data needed to support expanding the indication of the HeartBeam System beyond arrhythmia assessment to include heart attack assessment.
Heart attacks remain the leading cause of death, with more than 20 million patients in the U.S. who are at risk. Patients often delay seeking care by 3–4 hours because symptoms can be vague or subtle, driving up mortality, complications, and cost of care. While a 12-lead ECG remains the standard of care for diagnosing a heart attack, there is no reliable method for physicians to assess possible heart attacks outside of a clinical setting. HeartBeam aims to fill this gap and shorten “symptom-to-door” times by enabling patients to record a clinical-grade ECG the moment symptoms begin, wherever they are. By capturing the heart’s electrical signals in 3D, from 3 non-coplanar dimensions, HeartBeam’s 3D ECG technology provides physicians with a high-fidelity, reliable way to assess possible heart attacks outside of a clinical setting.
“Every minute matters during a heart attack, and early, accurate identification of a heart attack is essential to ensuring patients receive the care they need in a timely manner and improving outcomes,” said HeartBeam Scientific Advisory Board Chair C. Michael Gibson, MD, FRCP, FAHA, FSCAI, FACC, Interventional Cardiologist at Beth Israel Lahey and Professor of Medicine at Harvard Medical School. “HeartBeam’s technology has the potential to meaningfully change how quickly we evaluate patients by providing timely access to clinical-grade ECG data outside the hospital, enabling clinicians to accelerate triage decisions and intervene sooner.”
The ALIGN-ACS pilot study is designed to enroll 100 patients presenting with chest pain in the emergency room (ER). Patients will be evaluated with both a standard 12-lead ECG and the HeartBeam device and both results will be compared with each patient’s final diagnosis at discharge. As the study is designed to enroll chest pain patients in the ER, enrollment is expected to progress quickly.
The pilot study builds on multiple earlier proof of concept studies demonstrating that a 3D ECG configuration similar to the HeartBeam device’s ability to detect heart attacks was similar in accuracy to a standard 12-lead ECG, including a study presented at the 2025 American Heart Association Scientific Sessions on the 3D approach. Learnings from the ALIGN-ACS pilot study will inform the design of a multicenter pivotal study that would serve as the basis of a future FDA submission.
“HeartBeam was founded on the premise that since most heart attacks happen outside of a hospital, there should be a fast and easy way for patients and physicians to assess both symptoms and ECG data at home or anywhere,” said Robert Eno, Chief Executive Officer for HeartBeam. “The initiation of our pilot study for heart attack detection is a defining moment for HeartBeam as this is one of the largest clinical opportunities in cardiology. Our platform is uniquely positioned to deliver clinical-grade ECG insights at the moment symptoms occur and facilitate more timely action to close the ‘symptom-to-door’ gap.”
This milestone aligns directly with HeartBeam’s key long-term growth initiatives, which also include the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam received FDA clearance for arrhythmia assessment for its 3D ECG technology in December 2024 and for its 12-Lead ECG synthesis software in December 2025 1 . The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com .
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov . We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
1 Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
MKT-109 v1
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305231175/en/
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
FAQ**
How will HeartBeam Inc. BEAT utilize data from the ALIGN-ACS pilot study to support future FDA submissions for heart attack assessment indications?
What specific market potential does HeartBeam Inc. BEAT foresee with over million patients at risk of heart attacks, and how does this influence their long-term growth strategy?
How does HeartBeam Inc. BEAT's ECG technology differ from traditional methods, and what advantages does it offer in emergency care settings?
What further developments are planned for the HeartBeam System to enhance its capabilities for monitoring cardiac health beyond arrhythmia assessment?
**MWN-AI FAQ is based on asking OpenAI questions about Heartbeam Inc. (NASDAQ: BEAT).
NASDAQ: BEAT
BEAT Trading
1.42% G/L:
$1.425 Last:
203,256 Volume:
$1.39 Open:
